BioDlink Biopharm

BioDlink (formerly TOT BIOPHARM) is a leading clinical-stage biopharmaceutical company and CDMO based in Suzhou, China, specializing in the development and commercialization of oncology therapies, particularly monoclonal antibodies and antibody-drug conjugates (ADCs). The company operates a fully integrated "one-site" platform that spans early-stage R&D, process development, and large-scale GMP manufacturing with a capacity exceeding 20,000 liters. BioDlink has successfully commercialized its self-developed bevacizumab biosimilar (TAB008) in multiple global markets and provides end-to-end CDMO services to international partners, including the manufacturing support for the world's first approved EGFR-targeted ADC. Its proprietary technologies, such as GL-DisacLink® for site-specific conjugation and BDKcell® for cell line development, position it as a key player in the complex biologics and ADC space.